Octanate (Human Coagulation Factor Viii)

Human Coagulation Factor VIII supplied by Octanate binds to activated factor IX on platelet surfaces, forming the intrinsic tenase complex. This complex dramatically accelerates the conversion of factor X to factor Xa, leading to thrombin generation and fibrin clot formation, thereby correcting the coagulation defect in hemophilia A.

The dose of Octanate is individualized by the prescribing clinician based on the patient’s weight, severity of hemophilia, type of bleed, and surgical requirements. The prescriber determines the amount of factor VIII units needed to achieve target plasma levels and adjusts subsequent dosing according to clinical response and laboratory monitoring.

Safety data for Octanate during pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should evaluate each case individually and discuss potential risks and benefits with the patient.

To order Octanate, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After the enquiry, the sales team will request trade or institutional credentials, then provide pricing, availability, cold‑chain shipping details, and necessary import documentation.

Octanate is a recombinant, plasma‑free factor VIII concentrate, offering high purity and low risk of viral transmission compared with plasma‑derived products. Compared with other recombinant brands (e.g., Advate, Kogenate), Octanate has a similar efficacy profile, but differences may exist in pharmacokinetics, dosing frequency, and formulation stability, which clinicians consider when selecting therapy.

Octanate must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature during use, it may be administered promptly but should not be re‑refrigerated for later use.

Octanate is administered by intravenous infusion. The solution is diluted according to the manufacturer’s instructions and infused over a period determined by the patient’s weight, the required dose, and clinical tolerance. Infusion rates are typically started slowly and may be increased if no adverse reactions occur.

The most serious risks include the development of inhibitory antibodies (inhibitors) that neutralize factor VIII activity, severe allergic or anaphylactic reactions, and rare thrombotic events such as deep‑vein thrombosis. Patients should be monitored for signs of inhibitor formation and any acute hypersensitivity during and after infusion.

Octanate should not be used in patients with a known hypersensitivity to any component of the product, including the stabilizers. Individuals who have previously developed high‑titer inhibitors to factor VIII may require alternative therapies. Clinicians should assess each patient’s medical history before initiating treatment.